The South African Health Products Regulatory Authority (SAHPRA) has announced a recall of specific batches of Citro-Soda Regular, a widely used antacid, following identification of potential contamination risk at the Adcock Ingram manufacturing facility in Clayville, Johannesburg. The regulatory action was announced on 20 March 2026, with SAHPRA scheduling a media briefing to address safety concerns.
Key takeaways
- SAHPRA has ordered recall of specific Citro-Soda Regular batches due to contamination risk
- Contamination concern identified at Adcock Ingram’s Clayville manufacturing facility
- Recall limited to specified production batches, not all Citro-Soda products
Manufacturing facility contamination triggers recall
The recall follows safety concerns identified at the Adcock Ingram Clayville manufacturing facility in Johannesburg. SAHPRA’s announcement indicates the contamination risk is facility-specific rather than product-wide.
The South African regulatory authority has not disclosed the nature of the contamination or specific health risks associated with affected batches. Similar pharmaceutical recalls typically involve microbial contamination, chemical impurities, or manufacturing defects that could compromise patient safety.
For related pharmaceutical safety updates, visit our Pharmacy & Prescribing section for the latest regulatory actions and drug safety alerts.
Limited scope recall affects specific production batches
According to SAHPRA’s statement, the recall is limited to specified batches of Citro-Soda Regular rather than a comprehensive product withdrawal. This targeted approach suggests the contamination risk is contained to specific production runs from the Clayville facility.
Patients currently using Citro-Soda Regular should check batch numbers against SAHPRA’s recall list once published. Healthcare providers should advise patients to discontinue use of affected batches and seek alternative antacid treatments if necessary.
Our Quality & Safety coverage provides ongoing updates on pharmaceutical manufacturing standards and regulatory enforcement actions.
SAHPRA has scheduled a media briefing to address the contamination risk and recall procedures for Citro-Soda Regular batches manufactured at the Clayville facility.
— South African Health Products Regulatory Authority (March 2026)
What this means
Frequently asked questions
Which Citro-Soda products are affected by the recall?
The recall specifically targets Citro-Soda Regular batches manufactured at the Adcock Ingram Clayville facility. SAHPRA has not indicated that other Citro-Soda variants or products from different facilities are affected.
What type of contamination risk has been identified?
SAHPRA has not disclosed the specific nature of the contamination risk. The regulatory authority is expected to provide details during the scheduled media briefing.
How can patients identify affected batches?
Patients should wait for SAHPRA to publish the complete list of affected batch numbers and manufacturing dates. This information will be available following the media briefing.
The Citro-Soda recall highlights the importance of robust pharmaceutical manufacturing oversight and rapid regulatory response to potential safety risks. SAHPRA’s proactive approach demonstrates the critical role of national regulatory authorities in protecting public health through effective drug safety monitoring and enforcement actions.
Source: SAHPRA to brief media on the recall of specified batches of Citro-Soda Regular amid safety concerns
Was this article helpful?
Related Coverage
